STOCK TITAN

Pacira Biosciences Inc - PCRX STOCK NEWS

Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.

Overview

Pacira BioSciences Inc (NASDAQ: PCRX) is a specialty pharmaceutical company committed to revolutionizing pain management by offering innovative non-opioid therapies and regenerative health solutions. With a core focus on providing safe and effective alternatives for pain control, the company leverages its proprietary drug delivery platforms to address acute pain in surgical and chronic conditions. Its approach combines advanced pharmaceutical formulations with novel medical devices, ensuring that clinicians have access to effective treatment options that reduce reliance on opioids.

Core Technologies and Products

At the heart of Pacira's innovation is its unique product delivery technology, which encapsulates active compounds without altering their molecular structures. This platform enables controlled, extended release of medications, ensuring long-lasting efficacy. The company has successfully commercialized several non-opioid treatments:

  • EXPAREL: A long-acting local anesthetic designed to provide postsurgical pain control through sustained drug release, thereby reducing the need for opioids.
  • ZILRETTA: An extended-release intra-articular injection indicated for the management of osteoarthritis knee pain, offering patients prolonged relief.
  • iovera®: A handheld, drug-free device that applies controlled doses of cold therapy to targeted nerves, providing immediate and lasting pain relief.

In addition to these commercial products, Pacira is advancing its pipeline with a novel gene therapy candidate, PCRX-201. This locally administered therapy aims to treat osteoarthritis by regulating inflammatory pathways, thus addressing the root causes of pain and disability.

Market Position and Business Model

Pacira BioSciences operates at the intersection of innovative drug delivery and non-opioid pain management solutions. Its business model emphasizes:

  • Commercialization of Proven Therapies: The company has established a presence in markets requiring effective postsurgical and chronic pain management solutions, evidenced by the wide adoption of its therapies in diverse clinical settings.
  • Advanced R&D and Pipeline Development: By investing in robust research and development programs, along with strategic partnerships, Pacira continues to expand its portfolio and maintain competitive differentiation in the specialty pharmaceutical sector.
  • Regulatory and Reimbursement Strategies: With products that have secured critical reimbursement designations, Pacira enhances market access for its non-opioid therapies across different healthcare settings. This strategic emphasis supports clinician adoption and broader patient access.

Clinical and Commercial Significance

The company's focus on non-opioid pain management comes at a time when reducing opioid dependency is an urgent priority in healthcare. By developing treatments that not only manage pain effectively but also minimize opioid consumption, Pacira is addressing a key public health challenge. Its clinically validated products have been incorporated into pain management protocols in hospitals and outpatient settings alike, offering enduring benefits for patients and healthcare providers.

Innovative Edge and Future Pipeline

Pacira’s utilization of advanced drug delivery systems, such as multivesicular liposomes and precise cryoneurolysis, underscores its commitment to innovation. These technologies not only improve therapeutic outcomes but also facilitate streamlined billing and regulatory approval processes through established coding systems. With an evolving pipeline that includes gene therapy approaches, the company is poised to expand its reach into additional therapeutic areas, addressing unmet needs in the treatment of chronic and musculoskeletal pain.

Competitive Landscape and Differentiators

In a competitive market, Pacira differentiates itself through its deep expertise in non-opioid pain management and its commitment to technological advancements. The integration of robust clinical data, strategic reimbursement initiatives, and a focus on delivering sustained therapeutic benefits positions the company as a trusted innovator among healthcare practitioners. Unlike traditional pain management solutions that rely heavily on opioids, Pacira’s products are designed to provide effective relief with reduced risk of dependency, offering a clinically superior alternative in the evolving landscape of pain management.

Conclusion

With a comprehensive portfolio that spans commercial-stage products and a promising pipeline, Pacira BioSciences Inc stands as a key player in the specialty pharmaceutical industry. Its ongoing commitment to developing non-opioid pain therapies, underpinned by advanced drug delivery technologies and rigorous clinical validation, ensures that it remains an authoritative source of innovation and expertise in pain management and regenerative health.

Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ: PCRX) is set to participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET. The presentation will be virtual, and investors can access the pre-recorded audio via the company's website. Pacira is recognized for its leadership in non-opioid pain management, particularly through its long-acting local analgesic, EXPAREL®, which launched in April 2012. The company also acquired the iovera°® system in 2019 to enhance its offerings in regenerative health solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
conferences
-
Rhea-AI Summary

Pacira BioSciences reported preliminary net product sales for July 2021, achieving $40.9 million for EXPAREL and $1.0 million for iovera°. Additionally, EXPAREL's average daily sales were 117% of July 2020 levels. This growth is attributed to increasing adoption as a non-opioid analgesic during outpatient surgeries. The company acknowledges ongoing uncertainty in the elective surgery market due to potential COVID-19 variants. Monthly unaudited sales reporting will continue until clearer market visibility is established.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.23%
Tags
none
-
Rhea-AI Summary

PARSIPPANY, N.J., Aug. 4, 2021 - Pacira BioSciences (NASDAQ: PCRX) will present at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 10:20 AM ET. Interested parties can access the live audio via the company’s website. A replay will be available for two weeks post-event. Pacira is dedicated to non-opioid pain management and regenerative health solutions, highlighted by its long-acting analgesic, EXPAREL, launched in April 2012, and the acquisition of the iovera° system in April 2019.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
Rhea-AI Summary

Pacira BioSciences (PCRX) reported strong second quarter 2021 financial results with total revenues of $135.6 million, up from $75.5 million year-over-year. EXPAREL net sales reached $130.1 million, significantly higher than $73.0 million in Q2 2020. The company achieved a GAAP net income of $19.1 million (or $0.43 per share), a recovery from a loss in the same quarter last year. Adjusted EBITDA soared to $50.3 million. Pacira also announced FDA approval for an enhanced EXPAREL manufacturing process and a distribution agreement with Eurofarma for Latin America, indicating positive growth prospects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences has received FDA approval for an enhanced manufacturing process for its product EXPAREL (bupivacaine liposome injectable suspension), allowing it to double production capacity at a new 200-liter facility in Swindon, England. This move is anticipated to enhance gross margins and extend market exclusivity to January 2041 with the issuance of a new patent. The company aims to commence commercial sales of EXPAREL produced in this facility by the end of the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
-
Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) reported significant findings on the iovera° system from a study focused on total knee arthroplasty (TKA). The addition of preoperative iovera° treatment to a multimodal pain management protocol led to a remarkable 51% reduction in daily opioid consumption and notably decreased pain levels and hospital stay lengths. Analysis of 267 patients showed less than 17% had a hospital stay of two or more days compared to 99% in the control group. These outcomes highlight iovera°'s efficacy in enhancing post-surgical recovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its second quarter financial results on August 3, 2021, before U.S. market opening. Following the earnings release, a live conference call will occur at 8:30 a.m. ET. Participants can join the call by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international), using passcode 9991311. A replay will be available for one week post-call. Pacira is known for its commitment to non-opioid pain management, with flagship product EXPAREL® launched in 2012, and acquisition of iovera°® system in 2019.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
conferences earnings
-
Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) announced preliminary unaudited net revenue of $135.6 million for Q2 2021, primarily driven by EXPAREL sales of $130.1 million. Average daily sales of EXPAREL surged to 178% of last year for Q2 and to 120% for June. Despite ongoing challenges due to the COVID-19 pandemic impacting elective surgeries, the company remains optimistic about future growth as conditions normalize. The report also highlights increased interest in iovera° and the company's commitment to non-opioid pain management solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences, Inc. (Nasdaq: PCRX) has entered a distribution agreement with Eurofarma Laboratories S.A. for the commercialization of EXPAREL® in 19 Latin American countries, including Brazil and Mexico. This partnership aims to enhance Pacira's presence in a rapidly growing market, allowing Eurofarma to leverage its extensive experience in introducing innovative products. Pacira will earn royalties and milestone payments based on Eurofarma's success in this region, reinforcing its commitment to providing non-opioid pain management solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL and iovera° totaling $41.2 million and $1.0 million, respectively, for May 2021. Sales for EXPAREL showed strong growth, with average daily sales at 162% of May 2020 and 105% of April 2021. This growth is attributed to increased demand in outpatient and non-elective procedures, despite ongoing impacts from the COVID-19 pandemic. The company continues to report monthly sales data to provide clarity on market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none

FAQ

What is the current stock price of Pacira Biosciences (PCRX)?

The current stock price of Pacira Biosciences (PCRX) is $24.07 as of April 1, 2025.

What is the market cap of Pacira Biosciences (PCRX)?

The market cap of Pacira Biosciences (PCRX) is approximately 1.1B.

What is the core focus of Pacira BioSciences Inc?

Pacira BioSciences Inc specializes in developing and commercializing innovative non-opioid pain management therapies and regenerative health solutions for both acute and chronic conditions.

How does Pacira differentiate its products in the market?

The company leverages proprietary drug delivery platforms and advanced technologies, such as multivesicular liposomes and cryoneurolysis, to deliver sustained pain relief with reduced opioid reliance.

What are the key commercial-stage products offered by Pacira?

Pacira’s main products include EXPAREL, a long-acting local anesthetic; ZILRETTA, an extended-release intra-articular injection for osteoarthritis knee pain; and iovera®, a handheld device that uses controlled cold therapy for drug-free pain control.

What technology underpins Pacira's drug delivery system?

The company utilizes a proprietary platform that encapsulates drugs in multivesicular liposomes, allowing for controlled, extended release of the active ingredient without altering its molecular structure.

How does Pacira address the issue of opioid dependency?

By developing effective non-opioid pain management options, Pacira reduces the reliance on opioids by offering alternatives that provide long-lasting pain relief, thereby addressing a significant public health concern.

What is PCRX-201 and what potential does it hold?

PCRX-201 is an emerging gene therapy candidate designed to treat osteoarthritis by reducing inflammation at the source. Its localized administration and innovative design offer a potential breakthrough in long-term pain management.

Which healthcare settings benefit from Pacira's therapies?

Pacira's products are used across a variety of settings, including hospital surgical departments, outpatient centers, and clinics, where effective pain management is critical for post-surgical recovery and chronic condition management.

What role do reimbursement strategies play in Pacira's business model?

Strategic reimbursement initiatives, such as securing unique coding for its products, streamline the billing process and enhance market access, ensuring that healthcare providers can readily adopt Pacira’s non-opioid solutions.

How does Pacira support clinical decision-making and patient care?

Through rigorous clinical validation, advanced drug delivery technologies, and continuous innovation, Pacira provides healthcare practitioners with reliable, evidence-based alternatives for effective pain management.
Pacira Biosciences Inc

Nasdaq:PCRX

PCRX Rankings

PCRX Stock Data

1.11B
44.62M
3.18%
111.99%
12.66%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
TAMPA